Out of the shadows: CXC chemokines in promoting aberrant lung cancer angiogenesis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Lung Angiogenesis Requires CD4(+) Forkhead Homeobox Protein-3(+) Regulatory T Cells.American journal of respiratory cell and molecular biology · 2015
   Article
2. The inflammatory tumor microenvironment, epithelial mesenchymal transition and lung carcinogenesis.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2012
   Article
3. HGF Airway Over-expression Leads to Enhanced Pulmonary Vascularization without Induction of VEGF.Current angiogenesis · 2012
   Article
4. Snail promotes CXCR2 ligand-dependent tumor progression in non-small cell lung carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2009
   Article
5. Lung cancer.The New England journal of medicine · 2008
   Review

Corrections and comments

• Comment on
  Cyclic AMP-responsive element binding protein- and nuclear factor-kappaB-regulated CXC chemokine gene expression in lung carcinogenesis.2008

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as